References
- Ariens E. J., Wius E. W., Veringer E. J. Stereoselectivity of bioactive xenobiotics. Biochemical Pharmacology 1988; 37: 9–18
- Bai S. A., Walle U. K., Wilson M. J., Walle T. Stereoselective binding of the (‐)‐enantiomer of propranolol to plasma and extravascular binding sites in the dog. Drug Metabolism and Disposition 1983; 11: 394–395
- Beckett A. J., Chidomere E. C. The identification and analysis of mexiletine and its metabolic products in man. Journal of Pharmacy and Pharmacology 1977a; 29: 281–285
- Beckett A. J., Chidomere E. C. The distribution, metabolism and excretion of mexiletine in man. Postgraduate Medical Journal 1977b; 53(suppl. 1)60–66
- Campbell N. P. S., Kelly J. G., Adgey A. A. J., Shanks R. G. Mexiletine in normal volunteers. British Journal of Clinical Pharmacology 1978; 6: 372–373
- Drayer D. E. Pharmacodynamic and pharmacokinetic differences between enantiomers in humans: an overview. Clinical Pharmacology and Therapeutics 1986; 40: 125–133
- Eichelbaum M., Mikus G., Vogelgesang B. Pharmacokinetics of ( + )‐, (‐), and ( + )‐verapamil after intravenous administration. British Journal of Clinical Pharmacology 1984; 18: 453–458
- Grech‐Belanger O., Turgeon J., Gilbert M. Stereoselective disposition of mexiletine in man. British Journal of Clinical Pharmacology 1986; 21: 481–487
- Haselbarth V., Doevendans J. E., Wolf J. E. Kinetics and bioavailability of mexiletine in healthy subjects. Clinical Pharmacology and Therapeutics 1981; 29: 729–736
- Kawashima K., Levy A., Spector S. Stereospecific radioimmuno‐assay for propranolol isomers. Journal of Pharmacology and Experimental Therapeutics 1976; 193: 517–523
- McErlane K. M., Igwemezie L., Kerr C. R. Stereoselective serum protein binding of mexiletine enantiomers in man. Research Communications in Chemical Pathology and Pharmacology 1987a; 56: 141–144
- McErlane K. M., Igwemezie L., Kerr C. R. Stereoselective analysis of the enantiomers of mexiletine by high‐performance liquid chromatography using fluorescence detection and study of their stereoselective disposition in man. Journal of Chromatography, Biomedical Applications 1987b; 415: 335–346
- Metzler C. M. NONLIN: A computer program for parameter estimation in non‐linear situations. Upjohn Company, Michigan 1974
- Prescott L. F., Clements J. A., Pottage A. Absorption, distribution and elimination of mexiletine. Postgraduate Medical Journal 1977; 53(suppl. 1)50–55
- Rowland M., Tozer T. N. Clinical Pharmacokinetics: concepts and applications. Lea and Febiger, London 1980; 53
- Sedman A. J., Wagner J. G. AUTOAN: A decision making pharmacokinetic computer program. Publication Distribution Services, Michigan 1976
- Simonyi M. On chiral drug action. Medicinal Research Reviews 1984; 4: 359–413
- Tocco D. J., Hooke K. F., Duncan A. E. W. Stereospecific binding of timolol, a beta‐adrenergic blocking agent. Drug Metabolism and Disposition 1976; 4: 323–329
- Walle K. U., Walle T., Bai S. A., Oranoff L. S. Stereoselectic binding of propranolol to human plasma, α,‐acid glycoprotein and albumen. Clinical Pharmacology and Therapeutics 1983; 34: 718–722
- Williams K., Lee E. Importance of drug enantiomers in clinical pharmacology. Drugs 1985; 30: 333–354
- Wilkinson G. R., Shand D. G. A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics 1975; 18: 377–390